APYX NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

Apyx Medical Inc · Healthcare · Medical Devices

Open interactive chart View report data
Latest close 4.10 USD
4.6% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 5.1% above the Trend Line and sits at 71.0% of its 52-week range. The latest completed week returned 4.6%, after a -4.7% four-week move. The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers. Options positioning is volatility with 52/100 conviction, while the latest news-sentiment score is 54/100. Near-term considerations: volume confirmation is below normal; earnings are due in 3d.

Setup score 49 out of 100
Latest Close 4.10 USD 31 Jul 2026
1W Return 4.6% latest completed week
4W Return -4.7% short-term follow-through
12W Return 11.7% quarterly tape
Trend Breadth 92.3% 48 of 52 weeks active
Volume Ratio 0.5x vs 13-week average
What is working
  • The trend backdrop is active with a 9-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Price is above Fair Value, showing premium demand versus the model.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Activity pressure is negative, which weakens the current setup.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through 4.6% Latest completed week; four-week move -4.7%. Indicator stack 82/38 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Options pressure Volatility 52/100 conviction; expected move 31.1%. News sentiment 54/100 55 relevant articles in the latest sentiment read. Event risk 3d Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 5.1% above the Trend Line and sits at 71.0% of its 52-week range. The latest completed week returned 4.6%, after a -4.7% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.5x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.8712-week average 0.69

12-week confirmation

Trend active10/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure9/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership12/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.87Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -4.7% over four weeks, 11.7% over 12 weeks, and 134.3% over one year. The current trend has remained active for 9 consecutive weeks.

Performance by holding period

1W4.6%
4W-4.7%
12W11.7%
26W2.0%
52W134.3%
Active trend streak9 weeks
Active weeks in one year48
Trend breadth92.3%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure-0.13Latest activity-pressure read.
Pressure change-121.0%Four-week change in activity pressure.
Leadership7.93Latest relative-leadership reading.
RS change-36.9%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality ranks weakly versus its universe; growth is moderate; valuation is expensive relative to peers.

Open full factor analysis
Factor week 02 Aug 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength18/100Blend of value, momentum, and quality. Underlying universe rank 83; rank 1 is best.
Value18/100Relative valuation strength. Underlying universe rank 83; rank 1 is best.
Quality4/100Profitability and accounting quality. Underlying universe rank 97; rank 1 is best.
Momentum97/100Medium-term price momentum. Underlying universe rank 4; rank 1 is best.
Growth78/100Revenue and earnings growth. Underlying universe rank 23; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
3.1x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-3.7%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
32.3%
Gross profit retained from each unit of revenue.
Operating margin
-5.6%
Operating profit retained from revenue.
Free-cash-flow margin
-12.1%
Free cash flow generated from revenue.
Return on invested capital
-11.1%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
18.2%
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
4/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-5.4%
Net share repurchases relative to market value.
Shareholder yield
-5.4%
Dividend yield plus net buyback yield.
Net debt / EBITDA
-3.4x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Options positioningVolatility

APYX shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of n/a, expected move of 31.1%, and Sharemaestro trend signal active.

Conviction52/100
Expected move31.1%
Put/call volume
Pressure-88
Speculation2
Volatility96
Trend agreement18
Open options detail
Insider activity10 / 4

10 acquisitions and 4 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment54/100

Weighted news tone is neutral across 55 relevant articles.

13 positive · 40 neutral · 2 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings3dNext report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
Options expected move31.1%Nearest-chain priced movement where available.
52-week drawdown-19.3%Distance below the 52-week high.
13-week volatility8.6%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher14 of 2612 weeks finished lower.
Best week+19.9%Week of 8 May.
Worst week-17.7%Week of 1 May.
Latest week+4.6%Week of 31 Jul.

Shape of recent returns

Strong gains9
Modest gains5
Flat weeks0
Modest losses3
Sharp losses9
Recent vol8.6%13-week weekly-return volatility.
Base vol9.6%52-week weekly-return volatility.
Up/down split27/25Count of positive and negative weeks in the 52-week window.
Average skew8.8% / -5.2%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape53/100

Trend, activity pressure, participation, and risk combine to a 53/100 tape read.

 Indicator analysis80/100

Latest 12-week confirmation: trend 10/12, activity pressure 9/12, relative leadership 12/12.

Activity pressure 0.87; No reversal markers Factors31/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 83; Small Cap Core rank 84 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Options40/100

APYX shows volatility options pressure with a 52/100 conviction score, put-call volume ratio of n/a, expected move of 31.1%, and Sharemaestro trend signal active.

Volatility · Volatility expansion watch · Expected move 31.1% Sentiment54/100

Weighted news tone is neutral across 55 relevant articles.

Apyx Medical Corp (APYX) Technical Analysis: Support, Resistance, Indicators & Moving Averages Insiders10 / 4

10 acquisitions and 4 disposals in the latest 180-day insider tape.

 Earnings3d

Next report is scheduled for 06 Aug 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20264.10 USD4.6%3.90 USD2.41 USD-0.137.93337.6KOn
24 Jul 20263.92 USD-8.4%3.88 USD2.41 USD0.034.77286.4KOn
17 Jul 20264.28 USD-2.3%3.86 USD2.42 USD0.3313.06274.4KOn
10 Jul 20264.38 USD1.9%3.84 USD2.43 USD0.3911.72298.0KOn
3 Jul 20264.30 USD-4.4%3.82 USD2.44 USD0.6312.56614.7KOn
26 Jun 20264.50 USD9.5%3.81 USD2.45 USD0.8119.63595.4KOn
19 Jun 20264.11 USD-12.4%3.79 USD2.45 USD0.655.26571.0KOn
12 Jun 20264.69 USD4.9%3.79 USD2.47 USD0.6624.12946.3KOn
5 Jun 20264.47 USD11.9%3.76 USD2.49 USD0.4322.451.1MOn
29 May 20264.00 USD-3.3%3.74 USD2.50 USD0.125.76384.7KOff
22 May 20264.13 USD2.0%3.71 USD2.52 USD-0.1713.52664.4KOn
15 May 20264.05 USD10.4%3.68 USD2.53 USD-0.4013.841.3MOff
8 May 20263.67 USD19.9%3.64 USD2.55 USD-0.444.012.1MOff
1 May 20263.06 USD-17.7%3.62 USD2.56 USD-0.43-7.51852.0KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.